Open, randomized, controlled, multicenter phase III study comparing 5FU/ FA [fluorouracil + folinic acid] plus irinotecan (FOLFIRI) plus cetuximab [Erbitux; Merck] versus 5FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer

Trial Profile

Open, randomized, controlled, multicenter phase III study comparing 5FU/ FA [fluorouracil + folinic acid] plus irinotecan (FOLFIRI) plus cetuximab [Erbitux; Merck] versus 5FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CRYSTAL
  • Sponsors Merck KGaA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Mar 2017 According to a Merck KGaA media release, based on the data from this and other three studies (CTP: 15696, 37756 and 60760) the UK National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Erbitux (cetuximab) in combination with either FOLFIRI or FOLFOX as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC).
    • 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top